Polygenic effect on accelerated tau pathology accumulation in Alzheimer's disease: Implications for patient selection in clinical trials
Rubinski, A.; Frerich, S.; Malik, R.; Franzmeier, N.; Ramirez, A.; Dichgans, M.; Ewers, M.; the Alzheimer's Disease Neuroimaging Initiative (ADNI),
Show abstract
Progression of fibrillar tau is a key driver of dementia symptoms in Alzheimers disease (AD), but predictors of the rate of tau accumulation at patient-level are missing. Here we combined the to-date largest number of genetic risk variants of AD (n=85 lead SNPs) from recent GWAS to generate a polygenic score (PGS) predicting the rate of change in fibrillar tau. We found that a higher PGS was associated with higher rates of PET-assessed fibrillar-tau accumulation over a mean of 1.8 yrs (range = 0.6 - 4 yrs). This, in turn, mediated effects of the PGS on faster rates of cognitive decline. Sensitivity analysis showed that the effects were similar for men and women but pronounced in individuals with elevated levels of beta-amyloid and strongest for lead SNPs expressed in microglia. Together, our results demonstrate that the PGS predicts tau progression in Alzheimers disease, which could afford sample size savings by up to 34% when used alone and up to 61% when combined with APOE {varepsilon}4 genotype in clinical trials targeting tau pathology.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer 99%
- Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology 97%
- Hemispheric Asymmetry of Tau Pathology is Related to Asymmetric Amyloid Deposition in Alzheimer's Disease 97%
Similar papers in this journal
- Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease 98%
- Head-to-head comparison between plasma p-tau217 and Flortaucipir-PET in amyloid-positive patients with cognitive impairment 98%
- Tau-PET and in vivo Braak-staging as a prognostic marker in Alzheimer’s disease 97%
Similar papers in this journal
- Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease 98%
- Individual regional associations between Aβ-, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies 96%
- Age, sex and APOE -ε4 modify the balance between soluble and fibrillar β-amyloid in cognitively intact individuals: topographical patterns and replication across two independent cohorts 96%
Similar papers in this journal
- Default mode network tau predicts future clinical decline in atypical early Alzheimer’s disease 98%
- Tau-first subtype of Alzheimer's disease consistently identified across in vivo and post mortem studies 98%
- Selective vulnerability and resilience to Alzheimer's disease tauopathy as a function of genes and the connectome 98%